glp-1 roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo Roche broadens obesity drug plans

In addition, outcome measurements were also variable, as some studies measured symptoms of a mental illness, whilst others required a diagnosis

General guidelines and dosing for patients with T2D: Initiate pramlintide at the 60 mcg dose taken immediately prior to major meals Titrate pramlintide to 120 mcg dose after 3 or more days with no clinically significant nausea Optimize insulin to achieve glycemic targets once the maintenance dose of pramlintide is reached and blood glucose concentrations are stable Practical Tips for Patients On Pramlintide Start With a Low Dose and Titrate Slowly Pramlintide can cause nausea, anorexia and vomiting, especially in T1D where a more gradual titration is required

Declaration of interests We declare no competing interests

MOTS-c (10mg) research peptide

Side Effects to Watch For Most people tolerate GLP-1 medications well, but side effects can happen